Are peptides legal? FDA approval, compounding and 2026 rules

Are peptides legal? Four situations

Whether a peptide is legal depends on what it is and how it is sold; these are the four situations U.S. federal rules distinguish. This page covers federal rules only and is not legal advice.

The rest of this page explains the compounding part, which changed most in 2026. Sport rules are on the banned peptides page and research-use sales on the safety page.

Peptide compounding: the basic rules

Under section 503A of the federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound with a bulk drug substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or is on the 503A bulks list, which is set by rulemaking.^[1] While nominated substances are evaluated, the FDA sorts them into interim categories:^[1]

Biological products, such as tesamorelin since 2020, cannot be compounded under 503A or 503B at all.^[13][14]

Compounded peptides: the 2023–2026 timeline

The key dates run from September 2023, when several peptides entered Category 2, to October 30, 2026, when HHS published its policy.

HHS states that, for these peptides, "neither the placement nor the removal changed [their] status under section 503A".^[12] In other words, leaving Category 2 did not make them eligible. DSIP and LL-37 left the same way in April 2026, and the FDA took DSIP to its advisory committee regardless; it intends to review LL-37 before the end of February 2027.^[3]

The advisory committee vote

FDA staff recommended against all of the July 2026 peptides, citing gaps such as "lack of information on the safety profile and immunogenicity risks" for BPC-157 and "the absence of human data" for TB-500.^[9][10] HHS later reported that the committee voted in favor of including BPC-157, TB-500 and MOTS-c.^[12] As of our check, the FDA had not posted minutes with vote counts; press reports of the tallies could not be confirmed in a primary source, so we do not repeat them.^[7]

What the HHS policy does

The policy says HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A" when ten conditions are met.^[12]

Conditions include:^[12]

• active ingredient from an FDA-registered manufacturer, with a certificate of analysis for each lot;
• a patient-specific prescription;
• only one active ingredient per product, which leaves blends such as BPC-157 + TB-500 outside the policy;
• the label statement "This is a compounded drug product. Not for resale.";
• adverse events reported through FDA MedWatch;
• bioavailability documentation for oral forms, and only FDA-cleared syringes as devices.

HHS gave its reason as wanting to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers".^[12]

What the policy does not do

The HHS policy does not approve any peptide or change the 503A bulks list.

• It approves nothing. No peptide became an FDA-approved drug.
• It does not change the list. None of these peptides is on the 503A bulks list; that requires rulemaking.^[1]
• It is not binding. HHS calls it a draft that "is not binding on HHS or the public", and says it may revisit it "if … a safety signal or product quality issue arises."^[12]
• It does not cover research-use sellers. It applies to compounding by licensed pharmacies, facilities and physicians. See the safety page.
• It does not cover AOD-9604, selank, CJC-1295, ipamorelin, sermorelin, GHK-Cu, melanotan II or bremelanotide, and cagrilintide cannot be compounded at all.

Peptide pages

• Status tableEvery peptide on one page
• BlendsWhy single-ingredient rules matter
• CJC-1295 / ipamorelinThe 2024 votes in detail